Amarin Corporation plc
NNASDAQ:AMRNRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Amarin Corporation plc is a biopharmaceutical company focused on the development, commercialization, and advancement of therapeutics to improve cardiovascular health and reduce cardiovascular risk. The company primarily markets its lead product, Vascepa (icosapent ethyl) in the United States and Vazkepa in Europe, prescription-grade omega-3 fatty acid capsules used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia and to lower the risk of cardiovascular events. Amarin's broad product offerings center on cardiovascular disease treatments, specifically addressing lipid disorders through their omega-3 therapies. The company operates globally with commercial activities spanning the United States, Europe, and other international markets through partnerships and licensing arrangements. Founded in 1989 and headquartered in Dublin, Ireland, with operational facilities in the United States, Amarin has recently undergone major strategic changes focused on expanding its global presence and increasing operational efficiency. In 2025, Amarin completed a transition to a fully partnered commercialization model outside the United States, partnering with seven collaborators across nearly 100 countries to leverage established commercial infrastructure and drive broader access to its therapies. The company implemented a global corporate restructuring in 2025 designed to reduce operating expenses by an estimated $70 million over 12 months, including a significant workforce reduction in Europe to align with the new partnership model. Additionally, Amarin is focused on accelerating in-market demand in Europe through a partnership with Recordati to commercialize Vazkepa. These strategic initiatives reflect Amarin's efforts to adapt to market challenges, including competition from generic alternatives and a shifting operational footprint, while positioning for sustainable growth and improved cash flow. The company continues to invest in research and development to pursue additional cardiovascular therapeutics and enhance its portfolio. Amarin retains significant financial assets including nearly $300 million in cash and operates with no debt, supporting its ongoing strategic objectives and shareholder value creation efforts. The company sells products through wholesalers, regional distributors, and specialty pharmacy providers, serving diverse healthcare markets primarily focused on cardiovascular disease risk reduction. Amarin's corporate strategy emphasizes innovation, global market expansion through partnerships, and operational discipline to drive future growth.
Company News
Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
What Amarin (AMRN) Said on Its Q3 Earnings Call
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX)
Analyzing Amarin (NASDAQ:AMRN) & Elanco Animal Health (NYSE:ELAN)
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
Amarin Q2 Earnings Call Highlights
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?